By: Molly Chiu From: bcm.edu Loss of one copy of the DNA Ligase I (LIG1) gene in triple-negative breast cancers (TNBC) with TP53 mutations confers resistance to chemotherapy, but researchers at Baylor College of Medicine and collaborating institutions have identified a vulnerability in these cells and used it to their advantage. The team identified underlying molecular mechanisms of platinum resistance …
Researchers identified new indicators for HER2+ breast cancer response to therapy
By: Ana María Rodríguez, Ph.D. From: bcm.edu Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible treatment. Their decision is informed by a comprehensive molecular profile of the patient’s cancer samples that predicts the most likely response of the cancer to treatment. If the profile predicts a high likelihood of …
DAPK3 emerges as a new regulator of migration of triple-negative breast cancer cells
By: Ana María Rodríguez, Baylor College of Medicine From: medicalxpress.com Triple-negative breast cancer (TNBC) is the subtype of breast cancer that is the hardest to treat. TNBC patients account for more than 20,000 cases of this condition annually in the U.S. alone. They experience worse outcomes than patients with other breast cancer subtypes—their five-year mortality rate is about 40%. The …
KIPA shows promise in predicting chemotherapy response in triple negative breast cancer
Source: Baylor College of Medicine From: news-medical.net Researchers at Baylor College of Medicine and collaborating institutions are developing a strategy to predict the response of triple negative breast cancer (TNBC) to chemotherapy, which would be a valuable tool for physicians deciding on the treatment with better probability of success on an individual basis. The study appears in Cancer Research Communications, …
Breast cancer tumors disrupt the development of an immune response to favor their own growth
Source: Baylor College of Medicine From:.news-medical.net Researchers at Baylor College of Medicine and collaborating institutions have identified a strategy cancerous tumors use to remotely disrupt the development of an immune response that could stop their growth. Published in the journal Cell Stem Cell, the study shows in animal models that breast cancer tumors send molecular signals to the bone marrow, …
Researchers identify markers of chemotherapy resistance and outcome in triple negative breast cancer
By: Molly Chiu, Baylor College of Medicine From: medicalxpress.com Researchers at Baylor College of Medicine and the Broad Institute of MIT and Harvard and clinicians at Washington University in St. Louis have identified biological markers in triple negative breast cancer (TNBC) that are associated with resistance to chemotherapy treatment. The study is published in the journal Cancer Discovery and was …
Study finds a more effective treatment option for HER2 mutant metastatic breast cancer
Source: Baylor College of Medicine From: news-medical.net Breast cancers with HER2 mutations respond to the drug neratinib, but the responses are variable and often not durable. Looking to better understand the underlying cause of this variation, a team led by researchers at Baylor College of Medicine investigated whether different HER2 mutations drove different responses to therapy. They were able to …
Bone microenvironment fosters breast cancer metastatic behavior
By: Molly Chu From: bcm.edu Two studies led by Baylor College of Medicine shed new light on the unanswered question of why estrogen receptor-positive (ER+) breast cancer sometimes grows back in the bone and spreads to other tissues despite effective endocrine therapies directed at ER. Working with animal models that include patient tumor samples, the team discovered that the bone …
Examining resistance to breast cancer treatments
By: Molly Chiu From: bcm.edu The combination of CDK4/6 inhibitors with endocrine therapy is the standard of care for patients with estrogen receptor-positive (ER+) and HER2-negative (ER+/HER2-) metastatic breast cancer. However, a subset of patients will have tumors with intrinsic resistance to this therapy and most patients will develop resistant disease at some point during treatment. Researchers at the Lester …
Triggering antiviral immune response in certain breast cancers
By: Molly Chiu From: bcm.edu Researchers at Baylor College of Medicine have discovered how therapeutics targeting RNA splicing can activate antiviral immune pathways in triple negative breast cancers (TNBC) to trigger tumor cell death and signal the body’s immune response. A new study published in Cell shows that endogenous mis-spliced RNA in tumor cells mimics an RNA virus, leading tumor …
- Page 1 of 2
- 1
- 2